NCT06247501招募中2 期
Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Event free survival
研究概览
简要总结
This is a phase 2 clinical trial targeting pediatric and adolescent patients diagnosed with CD19-positive B-ALL, considered very high-risk group. The study aims to administer CD19 CAR-T therapy as an alternative to hematopoietic stem cell transplantation in patients eligible for such transplantation. The trial includes patients aged 25 or younger.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 25 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject eligibility criteria include individuals who are under the age of 25 at the time of SNUH-CD19-CAR-T administration. Confirmation of B-cell acute lymphoblastic leukemia diagnosed at the initial assessment by a treating physician for the first diagnosis is required. Immunophenotypic analysis of CD19 expression on leukemia cells must be confirmed through immune profiling at the time of the initial diagnosis of B-cell acute lymphoblastic leukemia. In patients experiencing hematologic relapse of B-cell acute lymphoblastic leukemia, CD19 expression should also be confirmed at the time of relapse confirmation.
- •Patients must achieve hematologic complete remission defined as less than 5% blasts in the bone marrow after the first-line or second-line chemotherapy (first salvage therapy). Eligible patients for hematopoietic stem cell transplantation, defined by indications for transplantation, include those meeting at least one of the following criteria:
- •Philadelphia chromosome-positive due to t(9;22)(q34;q11) translocation.
- •Hypodiploidy defined by fewer than 44 chromosomes.
- •E2A-HLF gene fusion due to t(17;19) translocation.
- •Detection of minimal residual disease (MRD) positive at 0.01% or higher by next-generation sequencing confirmed after consolidation therapy and maintenance therapy.
- •Failure of the first-line therapy.
- •Cases not meeting any of the above criteria but deemed eligible for hematopoietic stem cell transplantation based on the investigator's judgment.
排除标准
- •Patients who have undergone hematopoietic stem cell transplantation.
- •Individuals for whom an adequate or sufficient leukapheresis product suitable for the production of SNUH-CD19-CAR-T cannot be obtained or is unavailable.
- •Those known to be infected with the human immunodeficiency virus (HIV).
- •Presence of uncontrolled active infections, determined by the investigator's assessment. If appropriate treatment has been administered for the infection, and there are no signs of progression at the time of enrollment, it is considered controlled. Persistent fever without other symptoms is not interpreted as progressive infection.
- •Women who are pregnant or breastfeeding.
- •Individuals deemed clinically inappropriate for participation in the clinical trial based on the investigator's clinical judgment.
结局指标
主要结局
Event free survival
时间窗: above 3 year
次要结局
- Overall survival(above 3 year)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Orphan Indications for CD19 Redirected Autologous T CellsPediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow TransplantationNCT04276870Stephan Grupp MD PhD133
已完成
1 期
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesAcute Biphenotypic LeukemiaBlasts 5 Percent or More of Bone Marrow Nucleated CellsCD19 PositiveNon-Hodgkin LymphomaSmall Lymphocytic LymphomaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaMinimal Residual DiseaseNCT02529813M.D. Anderson Cancer Center26
招募中
2 期
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell LymphomaNCT04484012City of Hope Medical Center36
Unknown
1 期
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic LeukemiaCD19 PositiveRelapseRefractoryAcute Lymphoblastic LeukemiaNCT03275493Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd40
招募中
1 期
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.Acute Lymphoblastic LeukemiaNCT06752785Guangzhou Women and Children's Medical Center10